European Commission Approves Ritlecitinib for Severe AA European Commission Approves Ritlecitinib for Severe AA

This makes ritlecitinib the first medicine authorized by the EC to treat individuals with severe alopecia areata as young as 12 years of age.MDedge News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Alert Source Type: news